Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
From Pfizer Inc.
Via Business Wire
Tickers PFE ROIV
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Third-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Completes Acquisition of ReViral
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Provides Update on Ownership Interest in Haleon
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Tickers BHVN PFE
Pfizer Reports First-Quarter 2022 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Second-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
From Pfizer Inc.
Via Business Wire
Tickers BHVN PFE
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.